BR112013002370A2 - composto, composição farmacêutica e processo de preparação de um composto - Google Patents

composto, composição farmacêutica e processo de preparação de um composto

Info

Publication number
BR112013002370A2
BR112013002370A2 BR112013002370A BR112013002370A BR112013002370A2 BR 112013002370 A2 BR112013002370 A2 BR 112013002370A2 BR 112013002370 A BR112013002370 A BR 112013002370A BR 112013002370 A BR112013002370 A BR 112013002370A BR 112013002370 A2 BR112013002370 A2 BR 112013002370A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
compounds
relates
Prior art date
Application number
BR112013002370A
Other languages
English (en)
Inventor
Rehman Abdul Rauf Abdul
Ray Abhijit
A Cliffe Ian
Sattigeri Jitendra
Kumar Kewal
Kumar Khera Manoj
Kumar Yadav Neeraj
Kumar Bhatnagar Pradip
Srivastava Punit
Ghosh Dastidar Sunanda
Sattigeri Viswajanani
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of BR112013002370A2 publication Critical patent/BR112013002370A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

composto, composição farmacêutica e processo de preparação de um composto. a presente invenção refere-se a certos derivados do ácido hidróxi propiônico e aos processos pasra síntese dos mesmos. essa invenção também se refere a composições farmacológicas contendo os compostos da presente invenção, e métodos de tratamento de asma, artrite reumatoide, copd, rinite, osteoartrite, artrite psoriática, psoríase, fibrose pulmonar, inflamação pulmonar, síndrome de angústia respiratória aguda, periodontites, esclerose múltipla, gengivites , aterosclerose, olhos secos, proliferação neointimal, que leva a restenose e insuficiência de isquemia cardíaca, derrame, doencas renais, metástase tumoral, e outras desordens inflamatórias caracterizadas pela expressão gênica e hiperativação da matriz de metaloproteinase usando os compostos.
BR112013002370A 2010-07-30 2011-07-14 composto, composição farmacêutica e processo de preparação de um composto BR112013002370A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1810DE2010 2010-07-30
PCT/IB2011/053155 WO2012014114A1 (en) 2010-07-30 2011-07-14 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BR112013002370A2 true BR112013002370A2 (pt) 2017-06-20

Family

ID=44720049

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002370A BR112013002370A2 (pt) 2010-07-30 2011-07-14 composto, composição farmacêutica e processo de preparação de um composto

Country Status (11)

Country Link
EP (1) EP2598493A1 (pt)
JP (1) JP2013537533A (pt)
KR (1) KR20130042590A (pt)
CN (1) CN103119030A (pt)
AU (1) AU2011284397A1 (pt)
BR (1) BR112013002370A2 (pt)
CA (1) CA2807097A1 (pt)
CO (1) CO6680674A2 (pt)
MX (1) MX2013001240A (pt)
SG (1) SG187654A1 (pt)
WO (1) WO2012014114A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN103304634B (zh) * 2013-05-30 2015-04-29 温州芳植生物科技有限公司 基质金属蛋白酶-2多肽抑制剂及其应用
CN103254290B (zh) * 2013-05-30 2014-09-03 南通广泰生化制品有限公司 基质金属蛋白酶-2多肽抑制剂及其应用
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP6426194B2 (ja) 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
WO2015150366A1 (de) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Cyclisch substituierte phenolether-derivate und ihre verwendung
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
WO2015150364A1 (de) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Substituierte benzotriazinonbutansäuren und ihre verwendung
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
WO2015189117A1 (de) * 2014-06-12 2015-12-17 Bayer Pharma Aktiengesellschaft Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3937838A (en) 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
US3700681A (en) 1971-02-16 1972-10-24 Pfizer 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4011258A (en) 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
CY1273A (en) 1980-07-09 1985-03-08 Draco Ab 1-(dihydroxyphenyl)-2-amino-ethanol derivatives;preparation,compositions and intermediates
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
CA1240708A (en) 1983-11-15 1988-08-16 Johannes K. Minderhoud Process for the preparation of hydrocarbons
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
IL151250A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
BR0206771A (pt) 2001-01-30 2004-02-25 Pfizer Prod Inc Processos para a preparação de cidos cromanilbenzóicos
US6794510B2 (en) 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
GB0312654D0 (en) 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EA013539B1 (ru) 2005-02-22 2010-06-30 Рэнбакси Лабораториз Лимитед Производные 5-фенилпентановой кислоты в качестве ингибиторов матричной металлопротеиназы для лечения астмы и других заболеваний
AP2690A (en) 2006-08-22 2013-07-15 Ranbaxy Laboratoiries Ltd Matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
KR20130042590A (ko) 2013-04-26
CN103119030A (zh) 2013-05-22
AU2011284397A1 (en) 2013-02-21
MX2013001240A (es) 2013-08-27
CO6680674A2 (es) 2013-05-31
EP2598493A1 (en) 2013-06-05
CA2807097A1 (en) 2012-02-02
WO2012014114A1 (en) 2012-02-02
JP2013537533A (ja) 2013-10-03
SG187654A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
BR112013002370A2 (pt) composto, composição farmacêutica e processo de preparação de um composto
BR112013006929A2 (pt) composto de fórmula i, composição farmacêutica, processo para preparar os compostos de fórmula 9, 16, 20, 27 e 30
BR112013006932A2 (pt) composto composição farmacêutica e processo para preparar um composto
IT1401911B1 (it) Processo per la sintesi di acido 2,5-furandicarbossilico
BR112012019367A2 (pt) processo para integração de calor para produção de etanol e processo de purificação.
CU20110134A7 (es) Inhibidores de la metaloproteinasa matriz
BR112018013249A2 (pt) método de preparação de compostos de carboxilado de piridil pirraglidinona
BR112012016318A2 (pt) "alfa-amilase isolada, composição, método pra produzir amido liquefeito, processo para sintetizar um produto de fermentação, sequência de acidos nucleicos, célula hospedeira, e, método para preparar uma alfa-amilase."
BR112012019413A2 (pt) processo para producao de uma corrente de alimentacao de ester para producao de esteres e coproducao de etanol
ITMI20081164A1 (it) Processo per la produzione di esteri dell'acido levulinico da biomasse
BR112015006255A2 (pt) Métodos para a produção de produtos químicos e derivados dos mesmos
BR112013001245A2 (pt) método de produção de ingenol-3-angelato
BR112014018756A8 (pt) Processo para preparo de etil éster de ácido n-(4-ciclo-hexil-3-trifluorometil-benziloxi)-acetimídico
FI20105640L (fi) Menetelmä mikroselluloosan valmistamiseksi
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
BR112012017448A2 (pt) método para a preparação de sais de ácido metanossulfônico de tetrazol, e novo composto empregado no mesmo
BR112012016247A2 (pt) processo contínuo para a produção de derivados de ácidos carboxílicos saturados
FR2984343B1 (fr) Procede d'obtention par voie sol-gel d'un revetement fonctionnel durable pour supports, notamment textiles, et revetement ainsi obtenu
BR112015014895A2 (pt) processo para produção de produtos de biomassa
UA111868C2 (uk) Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти
BR112012013582A2 (pt) processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
BRPI0907872A2 (pt) Processo para produção de ácido dicarboxílico
ATE498606T1 (de) Herstellungsverfahren für n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)- - nitrobenzolsulfonylamidderivate
BR112012026205A2 (pt) processo para produção enzimática de um produto de fosfinotricina ou um precursor do mesmo
MX360369B (es) Acidos (3r,4r,5s)-5-guanidino-4-acetamido-3-(pentan-3-iloxi)cicloh exen-1-carboxilicos fluorosustituidos, sus esteres y uso de los mismos.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]